AI Article Synopsis
- Despite the use of antifungal agents in neutropenic patients, invasive fungal infections still significantly impact health and survival rates.
- There is insufficient evidence from solid randomized trials, except for fluconazole use in allogeneic marrow transplant patients, leading to uncertainty about the effectiveness of antifungal prophylaxis.
- Early diagnosis through noninvasive methods and proactive treatment strategies may be more effective than just relying on preventive medication.
Article Abstract
Despite the widespread prophylactic use of antifungal agents in neutropenic patients, invasive fungal infections continue to emerge as major causes of morbidity and mortality. With the exception of fluconazole prophylaxis in allogeneic marrow transplant recipients, no firm conclusions can be drawn due to the lack of reliable, randomized trials. At the present time, it seems that antifungal chemoprophylaxis is more a matter of faith rather than science. Earlier diagnosis based on noninvasive diagnostic techniques and pre-emptive strategies may offer more promise than a liberal prophylactic approach.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00001432-199912000-00004 | DOI Listing |
Publication Analysis
Top Keywords
antifungal prophylaxis
4
prophylaxis neutropenia
4
neutropenia despite
4
despite widespread
4
widespread prophylactic
4
prophylactic antifungal
4
antifungal agents
4
agents neutropenic
4
neutropenic patients
4
patients invasive
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!